BACKGROUND: Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria. Mapping the geographic extent of resistance is essential for planning containment and elimination strategies. METHODS:Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa). Patients received artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy. Parasite counts in peripheral-blood samples were measured every 6 hours, and the parasite clearance half-lives were determined. RESULTS: The median parasite clearance half-lives ranged from 1.9 hours in the Democratic Republic of Congo to 7.0 hours at the Thailand-Cambodia border. Slowly clearing infections (parasite clearance half-life >5 hours), strongly associated with single point mutations in the "propeller" region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from southern Vietnam to central Myanmar. The incidence of pretreatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission. In western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was associated with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days. CONCLUSIONS: Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is associated with mutations in kelch13. Prolonged courses of artemisinin-based combination therapies are currently efficacious in areas where standard 3-day treatments are failing. (Funded by the U.K. Department of International Development and others; ClinicalTrials.gov number, NCT01350856.).
RCT Entities:
BACKGROUND:Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria. Mapping the geographic extent of resistance is essential for planning containment and elimination strategies. METHODS: Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa). Patients received artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy. Parasite counts in peripheral-blood samples were measured every 6 hours, and the parasite clearance half-lives were determined. RESULTS: The median parasite clearance half-lives ranged from 1.9 hours in the Democratic Republic of Congoto 7.0 hours at the Thailand-Cambodia border. Slowly clearing infections (parasite clearance half-life >5 hours), strongly associated with single point mutations in the "propeller" region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from southern Vietnam to central Myanmar. The incidence of pretreatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission. In western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was associated with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days. CONCLUSIONS:Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is associated with mutations in kelch13. Prolonged courses of artemisinin-based combination therapies are currently efficacious in areas where standard 3-day treatments are failing. (Funded by the U.K. Department of International Development and others; ClinicalTrials.gov number, NCT01350856.).
Authors: Harald Noedl; Youry Se; Kurt Schaecher; Bryan L Smith; Duong Socheat; Mark M Fukuda Journal: N Engl J Med Date: 2008-12-08 Impact factor: 91.245
Authors: Ian H Cheeseman; Becky A Miller; Shalini Nair; Standwell Nkhoma; Asako Tan; John C Tan; Salma Al Saai; Aung Pyae Phyo; Carit Ler Moo; Khin Maung Lwin; Rose McGready; Elizabeth Ashley; Mallika Imwong; Kasia Stepniewska; Poravuth Yi; Arjen M Dondorp; Mayfong Mayxay; Paul N Newton; Nicholas J White; François Nosten; Michael T Ferdig; Timothy J C Anderson Journal: Science Date: 2012-04-06 Impact factor: 47.728
Authors: Achuyt Bhattarai; Abdullah S Ali; S Patrick Kachur; Andreas Mårtensson; Ali K Abbas; Rashid Khatib; Abdul-Wahiyd Al-Mafazy; Mahdi Ramsan; Guida Rotllant; Jan F Gerstenmaier; Fabrizio Molteni; Salim Abdulla; Scott M Montgomery; Akira Kaneko; Anders Björkman Journal: PLoS Med Date: 2007-11-06 Impact factor: 11.069
Authors: Olivo Miotto; Jacob Almagro-Garcia; Magnus Manske; Bronwyn Macinnis; Susana Campino; Kirk A Rockett; Chanaki Amaratunga; Pharath Lim; Seila Suon; Sokunthea Sreng; Jennifer M Anderson; Socheat Duong; Chea Nguon; Char Meng Chuor; David Saunders; Youry Se; Chantap Lon; Mark M Fukuda; Lucas Amenga-Etego; Abraham V O Hodgson; Victor Asoala; Mallika Imwong; Shannon Takala-Harrison; François Nosten; Xin-Zhuan Su; Pascal Ringwald; Frédéric Ariey; Christiane Dolecek; Tran Tinh Hien; Maciej F Boni; Cao Quang Thai; Alfred Amambua-Ngwa; David J Conway; Abdoulaye A Djimdé; Ogobara K Doumbo; Issaka Zongo; Jean-Bosco Ouedraogo; Daniel Alcock; Eleanor Drury; Sarah Auburn; Oliver Koch; Mandy Sanders; Christina Hubbart; Gareth Maslen; Valentin Ruano-Rubio; Dushyanth Jyothi; Alistair Miles; John O'Brien; Chris Gamble; Samuel O Oyola; Julian C Rayner; Chris I Newbold; Matthew Berriman; Chris C A Spencer; Gilean McVean; Nicholas P Day; Nicholas J White; Delia Bethell; Arjen M Dondorp; Christopher V Plowe; Rick M Fairhurst; Dominic P Kwiatkowski Journal: Nat Genet Date: 2013-04-28 Impact factor: 38.330
Authors: Carolina Gallego-Marin; Jacob E Schrum; Warrison A Andrade; Scott A Shaffer; Lina F Giraldo; Alvaro M Lasso; Evelyn A Kurt-Jones; Katherine A Fitzgerald; Douglas T Golenbock Journal: J Immunol Date: 2017-12-06 Impact factor: 5.422
Authors: Stella M Chenet; Sheila Akinyi Okoth; Julia Kelley; Naomi Lucchi; Curtis S Huber; Stephen Vreden; Alexandre Macedo de Oliveira; John W Barnwell; Venkatachalam Udhayakumar; Malti R Adhin Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Yvett Sosa; Roman Deniskin; I J Frame; Matthew S Steiginga; Deepak Bandyopadhyay; Todd L Graybill; Lorena A Kallal; Michael T Ouellette; Andrew J Pope; Katherine L Widdowson; Robert J Young; Myles H Akabas Journal: ACS Infect Dis Date: 2019-08-14 Impact factor: 5.084
Authors: Amed Ouattara; Aminatou Kone; Matthew Adams; Bakary Fofana; Amelia Walling Maiga; Shay Hampton; Drissa Coulibaly; Mahamadou A Thera; Nouhoum Diallo; Antoine Dara; Issaka Sagara; Jose Pedro Gil; Anders Bjorkman; Shannon Takala-Harrison; Ogobara K Doumbo; Christopher V Plowe; Abdoulaye A Djimde Journal: Am J Trop Med Hyg Date: 2015-04-27 Impact factor: 2.345
Authors: Costanza Tacoli; Prabhanjan P Gai; Claude Bayingana; Kevin Sifft; Dominik Geus; Jules Ndoli; Augustin Sendegeya; Jean Bosco Gahutu; Frank P Mockenhaupt Journal: Am J Trop Med Hyg Date: 2016-08-29 Impact factor: 2.345